192 related articles for article (PubMed ID: 6273020)
1. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement.
Feek CM; Ratcliffe JG; Seth J; Gray CE; Toft AD; Irvine WJ
Clin Endocrinol (Oxf); 1981 May; 14(5):451-8. PubMed ID: 6273020
[TBL] [Abstract][Full Text] [Related]
2. ACTH suppression after oral administration of cortisone in Addisonian and adrenalectomized patients.
Aanderud S; Myking OL; Bassøe HH
Acta Endocrinol (Copenh); 1982 Aug; 100(4):588-94. PubMed ID: 6289586
[TBL] [Abstract][Full Text] [Related]
3. Acutely raised corticotropin levels in Addison's disease are not associated with increased plasma arginine vasopressin and corticotropin-releasing factor concentrations in peripheral plasma.
Wittert GA; Livesey JH; Florkowski C; Or HK; Donald RA; Espiner EA
J Clin Endocrinol Metab; 1993 Jan; 76(1):192-6. PubMed ID: 8380605
[TBL] [Abstract][Full Text] [Related]
4. Variable sensitivity to the glucocorticoid activity of cortisol in patients with primary adrenal insufficiency: assessment with ACTH profiles.
Ekman B; Blomgren J; Andersson PO; Carlsson M; Arnqvist HJ
Horm Metab Res; 2010 Dec; 42(13):961-6. PubMed ID: 20925018
[TBL] [Abstract][Full Text] [Related]
5. Hyper-adrenocorticotropinemia in a patient with Addison's disease after treatment with corticosteroids.
Sugiyama K; Kimura M; Abe T; Ikezawa Y; Manaka H; Yamatani K; Tominaga M; Sasaki H; Misawa T
Intern Med; 1996 Jul; 35(7):555-9. PubMed ID: 8842762
[TBL] [Abstract][Full Text] [Related]
6. A possible ACTH secreting tumour of the pituitary developing in a conventionally treated case of Addison's disease.
Himsworth RL; Lewis JG; Rees LH
Clin Endocrinol (Oxf); 1978 Aug; 9(2):131-9. PubMed ID: 212238
[TBL] [Abstract][Full Text] [Related]
7. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
[TBL] [Abstract][Full Text] [Related]
8. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
[TBL] [Abstract][Full Text] [Related]
9. Probable ACTH-secreting pituitary tumour in association with Addison's disease.
Yanase T; Sekiya K; Ando M; Nawata H; Kato K; Ibayashi H
Acta Endocrinol (Copenh); 1985 Sep; 110(1):36-41. PubMed ID: 2994336
[TBL] [Abstract][Full Text] [Related]
10. GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.
Martins MR; Pinto AC; Brunner E; Silva MR; Lengyel AM
J Endocrinol Invest; 2003 Feb; 26(2):143-7. PubMed ID: 12739742
[TBL] [Abstract][Full Text] [Related]
11. The dose-response relationship of ACTH and cortisol in Cushing's disease.
Wolfsen AR; Odell WD
Clin Endocrinol (Oxf); 1980 Jun; 12(6):557-68. PubMed ID: 6249521
[TBL] [Abstract][Full Text] [Related]
12. Effect of atrial natriuretic factor infusion on basal and CRH-stimulated ACTH, cortisol and aldosterone levels in patients with Cushing's or Addison's disease.
Ambrosi B; Sala C; Bochicchio D; Colombo P; Gazzano G; Fadin C; Morganti A; Faglia G
Clin Endocrinol (Oxf); 1994 May; 40(5):589-94. PubMed ID: 8013139
[TBL] [Abstract][Full Text] [Related]
13. Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.
Carr DB; Fisher JE; Rosenblatt M
Horm Metab Res; 1986 Aug; 18(8):569-73. PubMed ID: 3019857
[TBL] [Abstract][Full Text] [Related]
14. Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease.
Løvås K; Thorsen TE; Husebye ES
J Endocrinol Invest; 2006 Sep; 29(8):727-31. PubMed ID: 17033262
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
[TBL] [Abstract][Full Text] [Related]
16. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy.
Scott RS; Donald RA; Espiner EA
Clin Endocrinol (Oxf); 1978 Dec; 9(6):571-6. PubMed ID: 218754
[TBL] [Abstract][Full Text] [Related]
17. Effects of fludrocortisone withdrawal on plasma angiotensin II, ACTH, vasopressin, and potassium in patients with Addison's disease.
Oelkers W; Bähr V
Acta Endocrinol (Copenh); 1987 Jul; 115(3):325-30. PubMed ID: 3039766
[TBL] [Abstract][Full Text] [Related]
18. Positive rate-sensitive corticosteroid feedback mechanism of ACTH secretion in Cushing's disease.
Fehm HL; Voigt KH; Kummer G; Pfeiffer EF
J Clin Invest; 1979 Jul; 64(1):102-8. PubMed ID: 221540
[TBL] [Abstract][Full Text] [Related]
19. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess.
Colombo P; Passini E; Re T; Faglia G; Ambrosi B
Clin Endocrinol (Oxf); 1997 Jun; 46(6):661-8. PubMed ID: 9274696
[TBL] [Abstract][Full Text] [Related]
20. [How should the plasma ACTH level in treated Addison's disease patients be interpreted?].
Pehuet-Figoni M; Bertagna X; Girard F; Bricaire H; Luton JP
Ann Endocrinol (Paris); 1989; 50(1):54-7. PubMed ID: 2543260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
